Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1590/0004-282X20200022
Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
Avaliação cognitiva em pacientes com hepatite C submetidos ao tratamento com Sofosbuvir e Simeprevir ou Daclatasvir![](https://www.thieme-connect.de/media/10.1055-s-00054595/202006/lookinside/thumbnails/10-1590-0004-282x20200022_20200022-1.jpg)
ABSTRACT
Background: Hepatitis C can be defined as an infectious disease that develops an inflammatory activity, which may cause an impairment in the central nervous system, may cause cognitive impairments and symptoms of depression. Objective: The objective of this study was to verify the cognitive performance of patients with chronic hepatitis C before and after treatment with simeprevir, sofosbuvir, and daclatasvir. Methods: A prospective study was carried out in three stages: before, right after treatment, and six months after. Fifty-eight patients under clinical follow-up were evaluated at the Emílio Ribas Infectology Institute, in São Paulo, Brazil. The following instruments were used: sociodemographic questionnaire, Lawton’s Scale, Beck’s Depression Inventory, and a battery of neuropsychological tests that evaluated: intellectual function, memory, attention, executive function, and motor and processing speed). For statistical analysis, the analyses described (mean, frequency, and standard deviation), chi-square, and ANOVA were used. Results: Most of the participants were male (n=30, 51.7%), with a mean of 58.23±8.79 years, mean schooling of 9.75±4.43 years. Comparing the results of neuropsychological evaluations (before, just after completion of drugs, and six months), a significant improvement was observed in relation to the acquisition of new knowledge (p=0.03), late visual memory (p=0.01), and tendency towards alternate attention (p=0.07). Conclusion: The treatment of the hepatitis C virus improved cognitive performance, especially in relation to memory.
RESUMO
Introdução: A hepatite C pode ser definida como uma doença infecciosa, que se desenvolve por uma atividade inflamatória, que pode gerar um comprometimento no Sistema Nervoso Central, podendo ocasionar prejuízos cognitivos e sintomas de depressão. Objetivo: O objetivo deste estudo foi verificar o desempenho cognitivo de pacientes com hepatite C crônica antes e após o tratamento com simeprevir, sofosbuvir e daclatasvir. Métodos: Foi realizado um estudo prospectivo em três etapas: antes, logo após o tratamento e seis meses depois. Foram avaliados 58 pacientes em acompanhamento clínico no Instituto de Infectologia Emílio Ribas, em São Paulo, Brasil. Foram utilizados os seguintes instrumentos: questionário sociodemográfico, Escala de Lawton, Inventário de Depressão de Beck e uma bateria de testes neuropsicológicos que avaliaram: função intelectual, memória, atenção, função executiva e velocidade motora e de processamento). Para análise estatística, foram utilizadas as análises descritas (média, frequência e desvio padrão), qui-quadrado e ANOVA. Resultados: A maioria dos participantes era do sexo masculino (n=30, 51,7%), com média de 58,23±8,79 anos, escolaridade média de 9,75±4,43 anos. Comparando os resultados das avaliações neuropsicológicas (antes, logo após a finalização dos medicamentos e seis meses), observou-se melhora significativa em relação à aquisição de novos conhecimentos (p=0,03), memória visual tardia (p=0,01) e tendência em relação a atenção alternada (p=0,07). Conclusão: O tratamento do vírus da hepatite C melhorou o desempenho cognitivo, principalmente em relação à memória.
Publication History
Received: 02 February 2020
Accepted: 06 February 2020
Article published online:
13 June 2023
© 2020. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Brasil. Ministério da Saúde. Programa Nacional de DST e AIDS - Boletim Epidemiológico - Hepatites Virais de 2018. Available from: http://www.aids.gov.br/pt-br/pub/2018/boletim-epidemiologico-de-hepatites-virais-2018
- 2 Focaccia R, da Conceicao OJ, Sette H Jr, Sabino E, Bassit L, Nitrini DR, et al. Estimated prevalence of viral hepatitis in the general population of the Municipality for review only Sao Paulo, measured by a serologic survey of a stratified, randomized and residence based population. Braz J Infect Dis. 1998 Dec;2(6):269-84.
- 3 Martins T, Narciso-Schiavon JL, Schiavon LL. Epidemiologia da infecção pelo vírus da hepatite C. Rev Ass Med Bras. 2011;57(1):107-12. https://dx.doi.org/10.1590/S0104-42302011000100024
- 4 Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002 Feb;35(2):440-6. https://doi.org/10.1053/jhep.2002.31257
- 5 Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003 Sep;9(6):847-54. https://doi.org/10.1017/S1355617703960048
- 6 Perry W, Carlson MD, Barakat F, Hilsabeck RC, Schiehser DM, Mathews C, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS. 2005 Oct;19 Suppl 3:S79-84. https://doi.org/10.1097/01.aids.0000192074.18691.31
- 7 Bragagnolo MA, Teodoro V, Lucchesesi LM, Ribeiro TCR, Tufik S, Kondo M. Detecção de encefalopatia hepatica minima através de testes neuropsicológicos e neurofisiológicos e o papel da amônia no seu diagnóstico. Arq Gastroenterol. 2009 Mar;46(1):43-9. https://doi.org/10.1590/S0004-28032009000100013
- 8 Kraus MR, Schafer A, Wißmann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther. 2005;77(1):90-100. https://doi.org/10.1016/j.clpt.2004.09.007
- 9 Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alfa: recognition and management. CNS Drugs. 2005:19(2):105-23. https://doi.org/10.2165/00023210-200519020-00002
- 10 Perry W, Hilsabeck RC, Hassanein T. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008 Aug;53:307-21. https://doi.org/10.1007/s10620-007-9896-z
- 11 Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol. 2015 Feb;21(8):2269-80. https://doi.org/10.3748/wjg.v21.i8.2269
- 12 Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schüler A, Ennen JC, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004 Nov;41(5):845-51. https://doi.org/10.1016/j.jhep.2004.07.022.
- 13 Senzolo M, Schiff S, D’Aloiso CM, Crivellin C, Cholongitas E, Burra P, et al. Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol. 2011 Aug;17:3369-74. https://doi.org/10.3748/wjg.v17.i29.3369
- 14 Iriana S, Curry MP, Afdhal NH. Neurologic manifestations of hepatitis C virus infection. Clin Liver Dis. 2017 Aug;21(3):535-42. https://doi.org/10.1016/j.cld.2017.03.008
- 15 Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7(5):468-73. https://doi.org/10.1038/sj.mp.4000995
- 16 Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LGC. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha -2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study. Arq Grastroenterol. 2006;43(4):275-79.
- 17 Strauss E. Hepatite C. Rev Soc Bras Med Trop. 2001;34(1):69-82.
- 18 Brasil. Ministério da Saúde. Programa Nacional de DST e AIDS. Protocolo Clínico e Diretrizes Terapêuticas para Hepatite Viral C e Coinfecções. Brasília: Ministério da Saúde; 2015.
- 19 Janssen-Cilag Farmacêutica Ltda. OLYSIO (simeprevir) - Bula do profissional de saúde aprovada pela ANVISA. 2015. Available from: http: www.anvisa.gov.br/datavisa/fila-bula/index.asp
- 20 Gilead Sciences Farmacêutica do Brasil Ltda. SOVALDI (sofosbuvir) - Bula do profissional de saúde aprovada pela ANVISA. 2015. Available from: http: www.anvisa.gov.br/datavisa/fila-bula/index.asp
- 21 Bristol-Myers Squibb Farmacêutica S.A. DAKLINZA (daclatasvir) - Bula do profissional de saúde aprovada pela ANVISA. 2015. Available from: http: www.anvisa.gov.br/datavisa/fila-bula/index.asp
- 22 Wechsler D. WAIS III- Escala de inteligência para adultos: manual. (Elizabeth Nascimento, Trad.). 1st ed. São Paulo: Casa do Psicólogo; 2004.
- 23 Miotto EC, Campanholo KR, Rodrigues MM, Serrao VT, Lucia MCS, Scaff M. Hopkins verbal learning test-revised and brief visuospatial memory test-revised: preliminary normative data for the Brazilian population. Arq Neuro-Psiquiatr. 2012 Dec;70(12):962-5. https://dx.doi.org/10.1590/S0004-282X2012001200014
- 24 Oliveira MS, Rigoni MS. Figuras Complexas de Rey: teste de cópia e de reprodução de memória de figuras geométricas complexas. São Paulo: Casa do Psicólogo ; 2010.
- 25 Campanholo KR, Romão MA, Machado MAR, Serrao VT, Coutinho DGC, Benute GRG, Lucia MCS. Performance of an adult Brazilian sample on the Trail Making Test and Stroop Test. Dement Neuropsychol. 2014;8(1):26-31. https://dx.doi.org/10.1590/S1980-57642014DN81000005
- 26 Spreen O, Strauss E. A compendium of neuropsychological tests: administration, norms, and commentary. 2nd ed. New York: Oxford Univ Press; 1998.
- 27 Brucki SMD, Malheiros SFM, Okamoto IH, Bertolucci PHF. Dados normativos para o teste de fluência verbal categoria animais em nosso meio. Arq Neuropsiquiatria. 1997;55(1):56-61.
- 28 Lafayette Instrument. Grooved Pegboard Test - Model 32025. User Instructions. Sagamore Parkaway North, USA: Lafayette Instrument; 2002. Available from: https://www.advys.be/docs/GroovedPegboardTestManual.pdf
- 29 Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 Autumn;9(3):179-86.
- 30 Gorestein C, Andrade L. Inventário de depressão de Beck: propriedades psicométricas da versão em português. Rev Psiquiatr Clin. 1998;25(5):245-50.
- 31 Henrique IFS, De Micheli D, De Lacerda RB, De Lacerda LA, Formigoni ML. Validação da versão brasileira do teste de triagem do envolvimento com álcool, cigarro e outras substâncias (ASSIST). Rev Assoc Med Bras. 2004;50(2):199-206. https://doi.org/10.1590/S0104-42302004000200039
- 32 American Psychiatric Association. Manual Diagnóstico e Estatístico de Transtornos Mentais: DSM-5. 5th ed. Porto Alegre: Artmed; 2014.
- 33 Kraus MR, MPsych AS, Wißmann S, Reimer P, Scheurlen P. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther. 2005;77(1):90-100. https://doi.org/10.1016/j.clpt.2004.09.007
- 34 Byrnes V, Miller A, Lowry D, Hill E, Weinstein C, Alsop D, et al. Effects of antiviral therapy and HCV clearance on cerebral metabolism and cognition. J Hepatol. 2012 Mar;56(3):549-56. https://doi.org/10.1016/j.jhep.2011.09.015
- 35 Kraus MR, Schäfer A, Teuber G, Porst H, Sprinzl K, Wollschläger S, et al. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology. 2013 Aug;58(2):497-504. https://doi.org/10.1002/hep.26229
- 36 Barbosa MED, Zaninotto AL, Mazo DFC, Pessoa MG, Souza de Oliveira CPM, Carrilho FJ, et al. Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin. BMC Gastroenterol. 2017;17:122. https://doi.org/10.1186/s12876-017-0679-5
- 37 Kleefeld F, Heller S, Ingiliz P, Jessen H, Petersen A, Kopp V, et al. Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients, effect on cognitive function, fatigue, and mental healths. J. Neurovirol. 2018;24:557-69. https://doi.org/10.1007/s13365-018-0647-z
- 38 Marciniewicz E, Podgórski P, Pawłowski T, Małyszcza K, Fleischer-Stępniewska K, Knysz B, et al. Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study. J Neurol Sci. 2019 Apr;399:36-43. https://doi.org/10.1016/j.jns.2019.02.002
- 39 Hahn D, Strokes CS, Kauser P, Meyer MR, Lanmert F, Gruenhage F,. Antidepressant effects of direct - acting antivirals against hepatitis C virus -Results from a pilot study. Eur J Clin Invest. 2018;48(12):e13024. https://doi.org/10.1111/eci.13024
- 40 Bichuetti DB, Oliveira ASB. Manifestações neurológicas nas hepatites virais. Rev Neurociênc. 2005 Sep;13(3):133-7. https://doi.org/10.34024/rnc.2005.v13.10351